Journal Scans
5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen
Fludarabine-Cyclophosphamide ± Oblimersen in Relapsed or Refractory CLL
S O'Brien, JO Moore, TE Boyd, LM Larratt, AB Skotnicki, B Koziner, AA Chanan-Khan, JF Seymour, J Gribben, LM Itri, KR Rai
20090808
2009 Sept 8
J Clin Oncol
5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen
J Clin Oncol. 2009 Sept 8; Epub ahead of print, S O'Brien, JO Moore, TE Boyd, LM Larratt, AB Skotnicki, B Koziner, AA Chanan-Khan, JF Seymour, J Gribben, LM Itri, KR Rai
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Purine nucleoside analog-based therapy, such as fludarabine, is often used as first-line therapy for chronic lymphocytic leukemia (CLL). Randomized studies comparing fludarabine plus cyclophosphamide (FC) (often with rituximab) have shown that FC significantly improves several outcomes, but not survival. The specific treatment for patients whose disease has relapsed after initial therapy often depends on disease-related characteristics, such as previous therapy and genomic abnormalities. A variety...
